NEW YORK (GenomeWeb) – Investment bank First Analysis has initiated coverage of NeoGenomics with an Overweight rating and a price target of $11, citing in part the company's more robust scale and product portfolio after its acquisition of Clarient.

With the integration of Clarient "well underway, NeoGenomics is positioned to take cancer diagnostics market share as a result of its increased scale and now broader and more comprehensive suite of offerings," First Analysis analyst Joseph Munda wrote in a research note Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.